Literature DB >> 19440974

Identification of three distinguishable phenotypes in golden retriever muscular dystrophy.

C E Ambrósio1, L Fadel, T P Gaiad, D S Martins, K P C Araújo, E Zucconi, M P Brolio, R F Giglio, A C Morini, T Jazedje, T R Froes, M L T Feitosa, M C Valadares, P C B Beltrão-Braga, F V Meirelles, M A Miglino.   

Abstract

Duchenne muscular dystrophy (DMD) is a human disease characterized by progressive and irreversible skeletal muscle degeneration caused by mutations in genes coding for important muscle proteins. Unfortunately, there is no efficient treatment for this disease; it causes progressive loss of motor and muscular ability until death. The canine model (golden retriever muscular dystrophy) is similar to DMD, showing similar clinical signs. Fifteen dogs were followed from birth and closely observed for clinical signs. Dogs had their disease status confirmed by polymerase chain reaction analysis and genotyping. Clinical observations of musculoskeletal, morphological, gastrointestinal, respiratory, cardiovascular, and renal features allowed us to identify three distinguishable phenotypes in dystrophic dogs: mild (grade I), moderate (grade II) and severe (grade III). These three groups showed no difference in dystrophic alterations of muscle morphology and creatine kinase levels. This information will be useful for therapeutic trials, because DMD also shows significant, inter- and intra-familiar clinical variability. Additionally, being aware of phenotypic differences in this animal model is essential for correct interpretation and understanding of results obtained in pre-clinical trials.

Entities:  

Mesh:

Year:  2009        PMID: 19440974     DOI: 10.4238/vol8-2gmr581

Source DB:  PubMed          Journal:  Genet Mol Res        ISSN: 1676-5680


  12 in total

Review 1.  Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies.

Authors:  Joe N Kornegay; Janet R Bogan; Daniel J Bogan; Martin K Childers; Juan Li; Peter Nghiem; David A Detwiler; C Aaron Larsen; Robert W Grange; Ratna K Bhavaraju-Sanka; Sandra Tou; Bruce P Keene; James F Howard; Jiahui Wang; Zheng Fan; Scott J Schatzberg; Martin A Styner; Kevin M Flanigan; Xiao Xiao; Eric P Hoffman
Journal:  Mamm Genome       Date:  2012-01-05       Impact factor: 2.957

Review 2.  Dystrophin-deficient large animal models: translational research and exon skipping.

Authors:  Xinran Yu; Bo Bao; Yusuke Echigoya; Toshifumi Yokota
Journal:  Am J Transl Res       Date:  2015-08-15       Impact factor: 4.060

3.  Systemic delivery of allogenic muscle stem cells induces long-term muscle repair and clinical efficacy in duchenne muscular dystrophy dogs.

Authors:  Karl Rouger; Thibaut Larcher; Laurence Dubreil; Jack-Yves Deschamps; Caroline Le Guiner; Gregory Jouvion; Bruno Delorme; Blandine Lieubeau; Marine Carlus; Benoît Fornasari; Marine Theret; Priscilla Orlando; Mireille Ledevin; Céline Zuber; Isabelle Leroux; Stéphane Deleau; Lydie Guigand; Isabelle Testault; Elisabeth Le Rumeur; Marc Fiszman; Yan Chérel
Journal:  Am J Pathol       Date:  2011-09-13       Impact factor: 4.307

Review 4.  The paradox of muscle hypertrophy in muscular dystrophy.

Authors:  Joe N Kornegay; Martin K Childers; Daniel J Bogan; Janet R Bogan; Peter Nghiem; Jiahui Wang; Zheng Fan; James F Howard; Scott J Schatzberg; Jennifer L Dow; Robert W Grange; Martin A Styner; Eric P Hoffman; Kathryn R Wagner
Journal:  Phys Med Rehabil Clin N Am       Date:  2012-02       Impact factor: 1.784

5.  Respiratory dysfunction in unsedated dogs with golden retriever muscular dystrophy.

Authors:  Justin C DeVanna; Joe N Kornegay; Daniel J Bogan; Janet R Bogan; Jennifer L Dow; Eleanor C Hawkins
Journal:  Neuromuscul Disord       Date:  2013-10-24       Impact factor: 4.296

6.  Adaptive Immune Response Impairs the Efficacy of Autologous Transplantation of Engineered Stem Cells in Dystrophic Dogs.

Authors:  Clementina Sitzia; Andrea Farini; Luciana Jardim; Paola Razini; Marzia Belicchi; Letizia Cassinelli; Chiara Villa; Silvia Erratico; Daniele Parolini; Pamela Bella; Joao Carlos da Silva Bizario; Luis Garcia; Marcelo Dias-Baruffi; Mirella Meregalli; Yvan Torrente
Journal:  Mol Ther       Date:  2016-08-10       Impact factor: 11.454

7.  Longitudinal ambulatory measurements of gait abnormality in dystrophin-deficient dogs.

Authors:  Inès Barthélémy; Eric Barrey; Pablo Aguilar; Ane Uriarte; Matthias Le Chevoir; Jean-Laurent Thibaud; Thomas Voit; Stéphane Blot; Jean-Yves Hogrel
Journal:  BMC Musculoskelet Disord       Date:  2011-04-13       Impact factor: 2.362

8.  Profiles of Steroid Hormones in Canine X-Linked Muscular Dystrophy via Stable Isotope Dilution LC-MS/MS.

Authors:  Helio A Martins-Júnior; Rosineide C Simas; Marina P Brolio; Christina R Ferreira; Felipe Perecin; Guilherme de P Nogueira; Maria A Miglino; Daniele S Martins; Marcos N Eberlin; Carlos E Ambrósio
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

9.  Motor physical therapy affects muscle collagen type I and decreases gait speed in dystrophin-deficient dogs.

Authors:  Thaís P Gaiad; Karla P C Araujo; Júlio C Serrão; Maria A Miglino; Carlos Eduardo Ambrósio
Journal:  PLoS One       Date:  2014-04-08       Impact factor: 3.240

10.  Differential Gene Expression Profiling of Dystrophic Dog Muscle after MuStem Cell Transplantation.

Authors:  Florence Robriquet; Aurélie Lardenois; Candice Babarit; Thibaut Larcher; Laurence Dubreil; Isabelle Leroux; Céline Zuber; Mireille Ledevin; Jack-Yves Deschamps; Yves Fromes; Yan Cherel; Laetitia Guevel; Karl Rouger
Journal:  PLoS One       Date:  2015-05-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.